TY - JOUR
T1 - Unlocking the promise of liquid biopsies in precision oncology
AU - Pando-Caciano, Alejandra
AU - Trivedi, Rakesh
AU - Pauwels, Jarne
AU - Nowakowska, Joanna
AU - Cavina, Beatrice
AU - Falkman, Lovisa
AU - Debattista, Jessica
AU - Belényesi, Szilárd-Krisztián
AU - Radhakrishnan, Periyasamy
AU - Molina, Mariano A.
PY - 2024/3/21
Y1 - 2024/3/21
N2 - Liquid biopsies have emerged as a promising and minimally invasive alternative to traditional tissue biopsies for detecting and monitoring cancer. Liquid biopsies offer a comprehensive analysis of cancer genetics and tumor burden by examining circulating cells and cell-derived analytes using a variety of assays, including conventional PCR methods and cutting-edge tools like long-read sequencing and nanotechnology. However, there are still some limitations and challenges that need to be overcome for their implementation in clinical routine, including the need for further research on their sensitivity and specificity, cost-effectiveness, standardization, and regulatory approval. Despite these challenges, liquid biopsies have the potential to become widely used tools in oncology. Here we provide an overview of the current state of liquid biopsies, highlighting recent advancements in the field and their potential benefits in clinical settings for cancer patients. The article further discusses the challenges that need to be addressed in order to facilitate their application worldwide. Prompt resolution of these challenges can be achieved by fostering international research collaborations and establishing standardized guidelines for liquid biopsy sample management and studies.
AB - Liquid biopsies have emerged as a promising and minimally invasive alternative to traditional tissue biopsies for detecting and monitoring cancer. Liquid biopsies offer a comprehensive analysis of cancer genetics and tumor burden by examining circulating cells and cell-derived analytes using a variety of assays, including conventional PCR methods and cutting-edge tools like long-read sequencing and nanotechnology. However, there are still some limitations and challenges that need to be overcome for their implementation in clinical routine, including the need for further research on their sensitivity and specificity, cost-effectiveness, standardization, and regulatory approval. Despite these challenges, liquid biopsies have the potential to become widely used tools in oncology. Here we provide an overview of the current state of liquid biopsies, highlighting recent advancements in the field and their potential benefits in clinical settings for cancer patients. The article further discusses the challenges that need to be addressed in order to facilitate their application worldwide. Prompt resolution of these challenges can be achieved by fostering international research collaborations and establishing standardized guidelines for liquid biopsy sample management and studies.
KW - Biomarker
KW - Cancer
KW - Clinical implementation
KW - Liquid biopsy
KW - Precision oncology
KW - Standardization
U2 - 10.1016/j.jlb.2024.100151
DO - 10.1016/j.jlb.2024.100151
M3 - Article
SN - 2950-1954
VL - 3
JO - The Journal of Liquid Biopsy
JF - The Journal of Liquid Biopsy
ER -